Magnokal (Potassium Hydrogen Aspartate Hemihydrate, Magnesium Aspartate Tetrahydrate)

Potassium hydrogen aspartate dissociates in the gastrointestinal tract, releasing potassium ions that are absorbed into the bloodstream. The potassium contributes to cellular functions like nerve impulse transmission and muscle contraction, helping to restore normal potassium levels and maintain electrolyte homeostasis.

The appropriate dose of Magnokal is determined by the prescribing healthcare professional based on the individual’s electrolyte status, age, renal function, and other clinical factors. Patients should follow the specific instructions provided by their prescriber and not adjust the dose on their own.

Safety data for Magnokal in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the supplement.

To order Magnokal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details, and any necessary import documentation.

Magnokal combines potassium hydrogen aspartate and magnesium aspartate in a single oral formulation, offering both potassium and magnesium replenishment. Compared with single‑ion supplements, it provides a broader electrolyte correction, which can be advantageous for patients needing simultaneous potassium and magnesium support.

Magnokal should be stored at ambient temperature below 25 °C. Keep the product in its original packaging, protect it from moisture, and store it out of direct sunlight to maintain stability and potency throughout its shelf life.

Magnokal is taken orally, typically with a glass of water. The exact timing (e.g., with meals or on an empty stomach) should follow the prescribing clinician’s guidance, which may consider the patient’s overall medication regimen and gastrointestinal tolerance.

The most serious risks include hyperkalemia and hypermagnesemia, which can lead to cardiac arrhythmias, muscle weakness, or respiratory depression. Severe allergic reactions such as anaphylaxis are also possible, though rare. Patients should seek immediate medical attention if they experience symptoms like palpitations, severe weakness, or breathing difficulty.

Magnokal should be avoided in individuals with known hypersensitivity to any of its ingredients, severe renal impairment, uncontrolled cardiac arrhythmias, or those taking medications that significantly raise potassium or magnesium levels without close monitoring. Healthcare providers should evaluate each patient’s medical history before prescribing.